Validation of neurodevelopmental assessments for early detection of high-risk infants in Zimbabwe: protocol for the Child Development Observation study (ChiDO study) - Scorecard - MDSpire
Conexiant’s news site is now MDSpire News. Learn more
Advertisement
Validation of Neurodevelopmental Evaluation Tools for Early Identification of High-Risk Infants in Zimbabwe: A Protocol for the Child Development Observation Study (ChiDO)
Clinical Scorecard: Validation of Neurodevelopmental Evaluation Tools for Early Identification of High-Risk Infants in Zimbabwe: A Protocol for the Child Development Observation Study (ChiDO)
At a Glance
Category
Detail
Condition
Neurodevelopmental Impairment (NDI)
Key Mechanisms
Validation of neurodevelopmental assessment tools for early detection of NDI in infants.
Target Population
Infants at risk for neurodevelopmental impairment associated with perinatal asphyxia and neonatal encephalopathy.
Care Setting
Low-resource settings in Harare, Zimbabwe.
Key Highlights
Study aims to validate GMA, HINE, and GSED tools for early NDI detection.
Approximately 600 caregiver-infant dyads will be enrolled.
Participants classified into low, moderate, and high-risk groups based on clinical concerns.
Comprehensive diagnostic evaluation for NDI will occur at 24 months.
Potential for earlier, low-cost identification of NDI in LMICs.
Guideline-Based Recommendations
Diagnosis
Utilize GMA, HINE, and GSED for assessing neurodevelopmental risk.
Management
Implement early interventions based on assessment outcomes.
Monitoring & Follow-up
Conduct longitudinal follow-up assessments at 3, 6, 12, 18, and 24 months.
Risks
Identify modifiable exposures that increase developmental-disorder risk.
Patient & Prescribing Data
Infants in low-resource settings with varying risk for NDI.
Early identification may facilitate timely interventions.
Clinical Best Practices
Conduct neurodevelopmental assessments in culturally adapted formats.
Ensure accessibility of assessment tools in LMICs.
Utilize observational assessments to reduce language dependence.
U.S. News & World Report has recognized Dana-Farber/Boston Children’s Cancer and Blood Disorders Center as the #1 pediatric cancer program in the nation in its 2026-2027 Best Children’s Hospitals report.
Phoenix Children’s today announced the appointment of Joshua D. Koch, MD, as Senior Vice President, Hospital Based In Chief, a newly established executive physician leadership role created to strengthen coordination across the health system’s hospital-based clinical services.
